Takeda: 12 NMEs Poised To Launch In Five Years, And Deliver $10 Bn In Peak Sales

The Japanese pharma held its first investor day in New York, outlining the company's strategy to deliver long-term growth through a newly energized oncology, gastrointestinal and rare disease pipeline.

KONSKIE, POLAND - JULY 21, 2018: Takeda Pharmaceutical company website displayed on a modern smartphone - Image
Takeda updated investors on its pipeline progress • Source: Shutterstock

Takeda Pharmaceutical Co. Ltd.’ efforts over the last five years to reshape its pipeline – including the merger with Shire PLC – are now poised to deliver. The Japanese pharma held its first ever investor day in New York on 14 November, coming after the company's stock was listed on the New York Stock Exchange in 2018 and the merger with Shire was completed in January.

With the integration of Shire largely completed, Takeda CEO Cristophe Weber, R&D president Andy Plump and other R&D leaders set...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.